Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Omeros Corporation is a commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market and orphan indications. The company's research and development efforts primarily target inflammation, complement-mediated diseases (focusing on its MASP-2 inhibitor narsoplimab and MASP-3 inhibitor OMS1029), and disorders of the central nervous system. Omeros also has a proprietary G protein-coupled receptor (GPCR) platform, GPR174, with potential applications in immuno-oncology. The company previously marketed OMIDRIA® for use during cataract surgery or intraocular lens replacement.
The headquarters serves as the central hub for Omeros's research and development, clinical operations, corporate strategy, finance, and administrative functions.
Located in the Lower Queen Anne neighborhood, the office building offers modern facilities and proximity to other technology and biotech companies. Specific architectural highlights are not widely publicized, but it is designed to support collaborative and innovative work.
The work culture at Omeros's Seattle headquarters is characterized by a strong focus on scientific innovation, collaboration across multidisciplinary teams, and a dedication to addressing unmet medical needs. The environment is often fast-paced, driven by research milestones and clinical development timelines typical of the biopharmaceutical industry.
Its Seattle location strategically places Omeros within a vibrant ecosystem of research institutions (like the University of Washington and Fred Hutchinson Cancer Research Center), biotech companies, and a skilled talent pool, fostering opportunities for collaboration and innovation.
While Omeros Corporation's primary operations and headquarters are based in Seattle, USA, its impact and activities, particularly in clinical development, regulatory affairs, and potential future commercialization, have a global scope. The company conducts clinical trials that often involve sites in multiple countries and collaborates with international partners, CROs, and CMOs to advance its therapeutic programs. Its engagement with regulatory bodies like the FDA (US), EMA (Europe), and others inherently involves a global perspective on drug development and approval standards.
201 Elliott Avenue West
Seattle
WA
USA
Address: Not Publicly Disclosed
The company's strategy appears focused on a centralized headquarters model, leveraging global partnerships, contract research organizations (CROs), and contract manufacturing organizations (CMOs) for broader operational reach rather than maintaining numerous physical international offices.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Omeros Corporation' leadership includes:
Omeros Corporation has been backed by several prominent investors over the years, including:
Over the last 12 months, Omeros Corporation appointed a new Chief Financial Officer and a Vice President of Regulatory Affairs and Quality. There was also a departure in a commercial leadership role.
Discover the tools Omeros Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Omeros Corporation likely utilizes standard corporate email formatting conventions. The most common patterns typically involve a combination of the employee's first name, last name, or initials followed by the @omeros.com domain.
[first_initial][last]@omeros.com
Format
gdemopulos@omeros.com
Example
85%
Success rate
Omeros Corporation Investor Relations • May 9, 2024
Omeros Corporation announced its financial results for the first quarter ended March 31, 2024. The company provided updates on its narsoplimab program for HSCT-TMA, its OMS906 program for paroxysmal nocturnal hemoglobinuria (PNH), and other pipeline developments....more
Omeros Corporation Investor Relations • April 1, 2024
Omeros Corporation announced the publication of a peer-reviewed manuscript in the journal *Protein Science*. The article details the discovery and characterization of the specific binding site of narsoplimab on MASP-2, its target lectin pathway enzyme, providing further insight into the drug's mechanism of action....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Omeros Corporation, are just a search away.